Anne‐Gaëlle Dosne

Author

Anne‐Gaëlle Dosne

Janssen (Belgium)ORCID

Also Known As

A. G. Dosne, A.-G. Dosne, Anne-Gaelle Dosne, Anne-Gaëlle Dosne, Anne‐Gaelle Dosne, Anne‐Gaëlle Dosne

Publications

525

Citations

H-Index

Concepts

All Affiliations

Janssen (Belgium)Uppsala University Janssen (United States)

About

Anne‐Gaëlle Dosne is an author at Janssen (Belgium) specializing in cancer research, immunotherapy, and tumor immunity.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	1	1	28
2	Immunology	1	1	28
3	Cancer Cell Biology	1	1	28
4	Cancer Therapeutics	1	1	28
5	Immune Surveillance	1	1	28

Anne‐Gaëlle Dosne

Publications

475

Citations

H-Index

Page 1

	Year	Citations
Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resampling Anne‐Gaëlle Dosne, Martin Bergstrand, Kajsa Harling, Journal of Pharmacokinetics and Pharmacodynamics	2016	245
An automated sampling importance resampling procedure for estimating parameter uncertainty Anne‐Gaëlle Dosne, Martin Bergstrand, Mats O. Karlsson Journal of Pharmacokinetics and Pharmacodynamics	2017	140
Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and <i>FGFR</i> alterations (FGFRa): Phase 2 continuous versus intermittent dosing. Yohann Loriot, Andrea Necchi, Se Hoon Park, Journal of Clinical Oncology ImmunologyFgfra MucUnresectable Urothelial CarcinomaImmunotherapeuticsImmunotherapy	2018	28
dOFV distributions: a new diagnostic for the adequacy of parameter uncertainty in nonlinear mixed-effects models applied to the bootstrap Anne‐Gaëlle Dosne, Ronald Niebecker, Mats O. Karlsson Journal of Pharmacokinetics and Pharmacodynamics	2016	14
Population Pharmacokinetics of Total and Free Erdafitinib in Adult Healthy Volunteers and Cancer Patients: Analysis of Phase 1 and Phase 2 Studies Anne‐Gaëlle Dosne, Elodie Valade, Kim Stuyckens, The Journal of Clinical Pharmacology	2019	13
Erdafitinib’s effect on serum phosphate justifies its pharmacodynamically guided dosing in patients with cancer Anne‐Gaëlle Dosne, Elodie Valade, Kim Stuyckens, CPT Pharmacometrics & Systems Pharmacology	2021	13
A translational model-based approach to inform the choice of the dose in phase 1 oncology trials: the case study of erdafitinib Elena M. Tosca, Nadia Terranova, Kim Stuyckens, Cancer Chemotherapy and Pharmacology	2021	11
Plasma and Liver Pharmacokinetics of the N-Acetylgalactosamine Short Interfering RNA JNJ-73763989 in Recombinant Adeno-Associated–Hepatitis B Virus–Infected Mice Louis Sandra, Huybrecht T’jollyn, Nele Goeyvaerts, Journal of Pharmacology and Experimental Therapeutics	2022	11

Page 1